

Thomas D Cook

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3177647/publications.pdf>

Version: 2024-02-01

20
papers

682
citations

840585

11
h-index

794469

19
g-index

21
all docs

21
docs citations

21
times ranked

946
citing authors

#	ARTICLE	IF	CITATIONS
1	Azithromycin for the Secondary Prevention of Coronary Heart Disease Events. JAMA - Journal of the American Medical Association, 2003, 290, 1459.	3.8	290
2	The microRNA miR-7a-5p ameliorates ischemic brain damage by repressing α -synuclein. Science Signaling, 2018, 11, .	1.6	78
3	Advanced Statistics: Up with Odds Ratios! A Case for Odds Ratios When Outcomes Are Common. Academic Emergency Medicine, 2002, 9, 1430-1434.	0.8	54
4	Advanced Statistics: Up with Odds Ratios! A Case for Odds Ratios When Outcomes Are Common. Academic Emergency Medicine, 2002, 9, 1430-1434.	0.8	47
5	Challenges of Non-Intention-to-Treat Analyses. JAMA - Journal of the American Medical Association, 2019, 321, 145.	3.8	40
6	Review of Draft FDA Adaptive Design Guidance. Journal of Biopharmaceutical Statistics, 2010, 20, 1132-1142.	0.4	31
7	The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study design. American Heart Journal, 2018, 201, 141-148.	1.2	22
8	P-Value Adjustment in Sequential Clinical Trials. Biometrics, 2002, 58, 1005-1011.	0.8	15
9	Analysis of Time-to-Event Data With Incomplete Event Adjudication. Journal of the American Statistical Association, 2004, 99, 1140-1152.	1.8	15
10	Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.7	15
11	Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort. International Journal of Cardiology, 2021, 326, 131-138.	0.8	13
12	Methods for mid-course corrections in clinical trials with survival outcomes. Statistics in Medicine, 2003, 22, 3431-3447.	0.8	12
13	Guidelines for Statistical Analysis Plans. JAMA - Journal of the American Medical Association, 2017, 318, 2301.	3.8	11
14	Not All Stem Cells Are Created Equal. Circulation Research, 2018, 123, 944-946.	2.0	10
15	Ancestral Folate Promotes Neuronal Regeneration in Serial Generations of Progeny. Molecular Neurobiology, 2020, 57, 2048-2071.	1.9	8
16	Missing data and sensitivity analysis for binary data with implications for sample size and power of randomized clinical trials. Statistics in Medicine, 2020, 39, 192-204.	0.8	8
17	The WIZARD Trial as a Case Study of Flexible Clinical Trial Design. Drug Information Journal, 2006, 40, 345-353.	0.5	5
18	Discussion of α -P-Value Calculation for Multistage Phase II Cancer Clinical Trials. Journal of Biopharmaceutical Statistics, 2006, 16, 777-780.	0.4	3

#	ARTICLE	IF	CITATIONS
19	Alternatives to Intention-to-Treat Analyses—Reply. JAMA - Journal of the American Medical Association, 2019, 321, 2135.	3.8	3
20	Stopping Trials Early Due to Harm. , 2022, 1, .		2